The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and significant returns is undeniable, the linked risks are also significant. Many of